


PHARMACEUTICAL 2022

ANI PHARMACEUTICALS INC Rank 106 of 475









RealRate

PHARMACEUTICAL 2022

ANI PHARMACEUTICALS INC Rank 106 of 475



The relative strengths and weaknesses of ANI PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ANI PHARMACEUTICALS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 180% points. The greatest weakness of ANI PHARMACEUTICALS INC is the variable Other Expenses, reducing the Economic Capital Ratio by 72% points.

The company's Economic Capital Ratio, given in the ranking table, is 40%, being 317% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	321,775
Cost of Goods Sold	0
Intangible Assets	322,010
Liabilities, Current	87,537
Liabilities, Non-Current	294,321
Other Assets	75,142
Other Compr. Net Income	8,382
Other Expenses	146,811
Other Liabilities	31,000
Other Net Income	-16,265
Property and Equipment	52,671
Research and Development	11,369
Revenues	216,136
Selling, General and Administrative Expense	84,294

Output Variable	Value in 1000 USD
Assets	771,598
Liabilities	412,858
Expenses	242,474
Stockholders Equity	358,740
Net Income	-42,603
Comprehensive Net Income	-38,412
Economic Capital Ratio	40%

